<div id="readability-page-1"><p>In a report released on December 9, Tony Ren from Macquarie maintained a Buy rating on BeiGene Ltd, with a price target of <span id="expert-recommendation-target">HK$236.00</span>. The company’s shares closed yesterday at HK$192.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Ren covers the Healthcare sector, focusing on stocks such as Chugai Pharmaceutical Co, CSPC Pharmaceutical Group, and Olympus. According to TipRanks, Ren has an average return of <span>12.6%</span> and a 58.70% success rate on recommended stocks. </p> <p>BeiGene Ltd has an analyst consensus of Strong Buy, with a price target consensus of HK$239.97.</p></div>

688235

BGNE

06160

<p>Macquarie's Tony Ren maintained a Buy rating on BeiGene Ltd with a price target of HK$236.00. The shares closed at HK$192.00. Ren, who covers the Healthcare sector, has an average return of 12.6% and a 58.70% success rate. BeiGene Ltd has a Strong Buy consensus with a price target of HK$239.97.</p>

Macquarie Sticks to Its Buy Rating for BeiGene Ltd (6160)